CCNA2 and SP1

Data Source:
BioGRID (affinity chromatography technology, pull down, affinity chromatography technology, pull down)

		CCNA2	SP1
Description		cyclin A2	Sp1 transcription factor
Image
GO Annotations	Cellular Component	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Cytosol Cyclin A2-CDK2 Complex	Chromatin Euchromatin Nucleus Nucleoplasm Cytoplasm Transcription Repressor Complex Protein-DNA Complex
	Molecular Function	Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding	Transcription Regulatory Region Sequence-specific DNA Binding RNA Polymerase II Transcription Regulatory Region Sequence-specific DNA Binding RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific Cis-regulatory Region Sequence-specific DNA Binding RNA Polymerase II Repressing Transcription Factor Binding DNA-binding Transcription Activator Activity, RNA Polymerase II-specific DNA Binding Double-stranded DNA Binding DNA-binding Transcription Factor Activity Protein Binding Protein C-terminus Binding Transcription Factor Binding Histone Acetyltransferase Binding Protein Homodimerization Activity Histone Deacetylase Binding BHLH Transcription Factor Binding Sequence-specific DNA Binding Metal Ion Binding Repressing Transcription Factor Binding HMG Box Domain Binding Sequence-specific Double-stranded DNA Binding
	Biological Process	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication Ras Protein Signal Transduction Viral Process Histone Phosphorylation Protein Deubiquitination Animal Organ Regeneration Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus	Regulation Of Transcription, DNA-templated Regulation Of Transcription By RNA Polymerase II Positive Regulation Of Gene Expression Viral Process Cellular Response To Insulin Stimulus Response To Hydroperoxide SnRNA Transcription By RNA Polymerase II Positive Regulation Of Blood Vessel Endothelial Cell Migration Positive Regulation By Host Of Viral Transcription Regulation Of Cholesterol Biosynthetic Process Positive Regulation Of Angiogenesis Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription By RNA Polymerase II Rhythmic Process Positive Regulation Of Amyloid-beta Formation Positive Regulation Of Hydrogen Sulfide Biosynthetic Process Positive Regulation Of Vascular Endothelial Cell Proliferation
Pathways		Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes Telomere Extension By Telomerase Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry	PPARA activates gene expression SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Activation of gene expression by SREBF (SREBP) Oncogene Induced Senescence RNA polymerase II transcribes snRNA genes RNA polymerase II transcribes snRNA genes Estrogen-dependent gene expression
Drugs		4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE Variolin B
Diseases
GWAS		Mean corpuscular hemoglobin ( 32888494)	Apolipoprotein B levels ( 32203549) High light scatter reticulocyte count ( 32888494) Hypospadias (moderate to severe) ( 31856834) Mean corpuscular hemoglobin ( 29403010) Mean corpuscular volume ( 29403010 32888494) Mean spheric corpuscular volume ( 32888494) Neutrophil percentage of white cells ( 27863252) Parkinsonism in frontotemporal lobe dementia ( 29724592) Percentage gas trapping ( 26030696) Progressive supranuclear palsy ( 30089514) Red blood cell count ( 32888494 27863252) Reticulocyte count ( 32888494 27863252) Reticulocyte fraction of red cells ( 32888494)
Interacting Genes		49 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR POLA1 PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 RPA1 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBE2C UBTF USP37	146 interacting genes: AATF AHR AKT1 AR ARHGAP21 ARNT ATF7IP ATF7IP2 BCL11B BCL6 BCOR BRCA1 CASP3 CASP6 CASP7 CBX5 CCNA1 CCNA2 CCND1 CD2 CDK1 CDK2 CEBPB CSNK2A1 CTCFL CTNNB1 DDX5 DROSHA E2F1 E2F2 E2F3 EGR1 ELF1 EP300 ESR1 ESR2 ESRRA ESRRB ESRRG ETS1 GABPA GATA1 GATA3 GATA4 HBZ HCFC1 HDAC1 HDAC2 HIF1A HINT1 HLTF HMGA1 HNF4A HOXC11 HSPA8 HTT IL1B JUN KIF1A KLF10 KLF4 KLF6 LDB1 LMO2 MAPK1 MAPK3 MAPK8 MBD1 MEF2C MEF2D MIER1 MIS18BP1 MSX1 MTREX MYC MYCN MYOD1 MYOG NAP1L1 NCOR1 NCOR2 NEPRO NFKB1 NFKB2 NFYA NFYB NFYC NKX3-1 NOS3 NPM1 NR2F1 NR5A1 NUP62 OGT PARP1 PER3 PML POGZ POU2F1 PPIG PPP1R13L PRKCZ PRKDC PSIP1 PSMC5 PURA RARA RB1 RBBP4 RBL1 REL RELA RNF4 RORA RXRA SENP6 SF3A1 SHC1 SMAD2 SMAD3 SMAD4 SMARCC1 SMARCC2 SOX10 SOX8 SP3 SP4 SREBF1 SREBF2 SRF SUB1 SUMO2 TAF4 TAL1 TBP TLX3 TP53 TP73 TPI1 USP39 VEGFA VHL YY1 ZBTB16 ZBTB2 ZBTB7A
Entrez ID		890	6667
HPRD ID		00453	01796
Ensembl ID		ENSG00000145386	ENSG00000185591
Uniprot IDs		P20248	P08047
PDB IDs		1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H 6RIJ	1SP1 1SP2 1VA1 1VA2 1VA3 6PV0 6PV1 6PV2 6PV3 6UCO 6UCP
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?